Hemostatic devices and methods of use
AssigneeTYRX, Inc.
InventorsSATISH PULAPURA, FATIMA BUEVICH, JORIE S. SOSKIN, FRANKLIN R. MANSFIELD, KAI R. WORRELL, CHARLIE WOOD
Life of this patent
Estimating the term…
Abstract
An anchorage device is provided that is configured to surround an implantable medical device. The anchorage device includes a first component having a first substrate and a second component having a second substrate. The second component is positioned within the first component. One of the first and second substrates includes a hemostatic agent and the other of the first and second substrates includes an active pharmaceutical ingredient. Kits, systems and methods are disclosed.
Claims20
An anchorage device configured to surround an implantable medical device, the anchorage device comprising:
- a first component comprising a first substrate;
- and
- a second component comprising a second substrate, the second component being positioned within the first component,
- wherein one of the first and second substrates comprises a hemostatic agent and the other of the first and second substrates comprises an active pharmaceutical ingredient.
An anchorage device configured to surround an implantable medical device, the anchorage device comprising:
- a first component comprising a first substrate;
- and
- a second component comprising a second substrate, the second component being positioned within the first component,
- wherein the first substrate comprises a first tyrosine-derived polyarylate and the second substrate comprises a second tyrosine-derived polyarylate, the first tyrosine-derived polyarylate comprising a hemostatic agent and the second tyrosine-derived polyarylate comprising an active pharmaceutical ingredient.
An anchorage device configured to surround an implantable medical device, the anchorage device comprising:
- a first component comprising a first substrate;
- and
- a second component comprising a second substrate, the second component being positioned within the first component,
- wherein the first substrate comprises a first tyrosine-derived polyarylate and the second substrate comprises a second tyrosine-derived polyarylate, the first tyrosine-derived polyarylate comprising tranexamic acid and the second tyrosine-derived polyarylate comprising rifampin and minocycline.
Dependencies are inferred from the claim text.